Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Human IgG1 (AS35)

Catalog number SAD-S35-100ug

Discontinued

Price for SAD-S35-100ug

Size / count 100 µg

This variant is discontinued and cannot be added to your cart.

About this product

Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Human IgG1 (AS35) (SAD-S35) is isolated from a SARS-CoV-2 infected patient and is recombinantly produced from human 293 cells (HEK293). This antibody recognizes the SARS-CoV-2 Spike Protein RBD domain and inhibits the interaction between SARS-CoV-2 RBD and ACE2 with an IC50 of 1.47 μg/mL using SARS-CoV-2 Inhibitor Screening Kit.<strong>Pseudovirus assay shows that this antibody has potent neutralizing activity against pseudovirus bearing SARS-CoV-2 Spike protein.</strong>

Specifications

Catalog number: SAD-S35-100ug
Size / count: 100 µg
Dry ice: No
Hazardous: No
Discontinued: Yes
Background: It's been reported that Coronavirus can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.
CAS Number: 9007-83-4
Host: HEK 293
Origin Species: Human
Target: Spike RBD
Conjugation: Unconjugated
Tag: Human IgG1 | Human Kappa
Stability: -20°C to -70°C for 12 months in lyophilized state; -70°C for 3 months under sterile conditions after reconstitution._x000D_For long term storage, the product should be stored at lyophilized state at -20°C or lower._x000D_Please avoid repeated freeze-thaw cycles.
Purity: 95%
Bioactivity: Immobilized SARS-CoV-2 S1 protein, His Tag at 2 μg/mL (100 μL/well) can bind Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Human IgG1 (AS35) (Cat. No. SAD-S35) with a linear range of 0.2-1.95 ng/mL (QC tested).
Format: Powder
Buffer: PBS, pH7.4
Additives: Trehalose
Shipping Conditions: Room Temperature
Storage Conditions: -20°C

Frequently Asked Questions

What is the catalog number for Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Human IgG1 (AS35)?

The catalog number for Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Human IgG1 (AS35) is SAD-S35-100ug.

Is Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Human IgG1 (AS35) in stock?

Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Human IgG1 (AS35) is currently made to order / not held in immediate stock. Contact us for lead time.

Who manufactures Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Human IgG1 (AS35)?

Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Human IgG1 (AS35) is manufactured by CRB.

What is the estimated delivery time for Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Human IgG1 (AS35)?

Estimated delivery time for Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Human IgG1 (AS35) is approximately 10 business day(s), depending on your location.

What is Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Human IgG1 (AS35) used for?

Is this product covered by a money-back guarantee?

Yes, we guarantee a full refund or store credit if this product arrives damaged beyond usability, or has a genuine performance issue under proper usage and storage, provided you report it immediately with evidence. Claims after the expiration date or due to improper storage after receipt are excluded.

Can this product be used for diagnostic or therapeutic purposes?

No. This product, like all items we supply, is intended for research laboratory use only and must not be used for diagnostics, therapeutics, treatment, or consumption by humans or animals.

What is the shelf life of this product?

Shelf life and expiration dates vary by product and are shown on the product listing and label. Products used beyond their expiration date are not eligible for performance-related returns or refunds, so please check the lot number and expiry before use.